PRESS RELEASE published on 05/09/2025 at 18:00, 1 year 2 months ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, resulting in EUR 100,000 capital increase, supporting innovative therapeutics development for vision preservation in elderly. Oxurion shares update post-capital increase Capital Increase Oxurion Atlas Special Opportunities, LLC Innovative Therapeutics Vision Preservation
BRIEF published on 04/25/2025 at 18:35, 1 year 3 months ago Oxurion Stops 2024 Transaction and Continues Negotiations for New Acquisition Acquisition Negotiations CRO Oxurion Biometrics
PRESS RELEASE published on 04/25/2025 at 18:30, 1 year 3 months ago Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025 Oxurion NV halts acquisition of French CRO, pursues deal with biometrics CRO to expand capabilities in clinical data management. Progress updates to follow Acquisition CRO Oxurion NV Clinical Data Management Biometrics
BRIEF published on 04/11/2025 at 20:05, 1 year 3 months ago Oxurion Publishes its 2024 Annual Report and Convenes its General Meeting Forward-looking Statements Annual Report 2024 Ophthalmic Therapies Shareholders' Meetings Oxurion NV
PRESS RELEASE published on 04/11/2025 at 20:05, 1 year 3 months ago Publication Annual Report - Annual Shareholders' Meeting Oxurion NV releases its annual report for the financial year 2024 and convenes its Annual Shareholders' Meeting in Leuven, Belgium. Developing ophthalmic therapies for retinal disease Shareholders' Meeting Annual Report Ophthalmic Therapies Oxurion NV Retinal Disease
BRIEF published on 04/04/2025 at 14:05, 1 year 3 months ago Oxurion General Meeting Postponed General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE published on 04/04/2025 at 14:00, 1 year 3 months ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 1 year 4 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 1 year 4 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 1 year 4 months ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
Published on 08/01/2026 at 01:20, 2 days 7 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 7 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 8 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 2 days 9 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/03/2026 at 08:30, 14 minutes ago Suspension - The Hospital Company (Dartford) Issuer PLC
Published on 08/03/2026 at 08:29, 15 minutes ago Launch of a €225 million tranche of its share buyback programme
Published on 08/03/2026 at 07:00, 1 hour 44 minutes ago BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 11 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 13 hours ago Share retention commitments (Dutreil Agreement)